Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.39
+0.06 (1.13%)
At close: Jan 21, 2025, 4:00 PM
5.41
+0.02 (0.37%)
After-hours: Jan 21, 2025, 7:22 PM EST
Verastem Employees
Verastem had 73 employees as of December 31, 2023. The number of employees increased by 16 or 28.07% compared to the previous year.
Employees
73
Change (1Y)
16
Growth (1Y)
28.07%
Revenue / Employee
$136,986
Profits / Employee
-$1,280,192
Market Cap
247.53M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VSTM News
- 6 days ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 7 days ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 8 days ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire
- 13 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Verastem: Planning The PDUFA Run-Up - Seeking Alpha
- 19 days ago - Verastem: BLA Acceptance Puts Key Goals In Sight - Seeking Alpha
- 21 days ago - Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? - Benzinga
- 22 days ago - Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - Business Wire